Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-02
2007-01-02
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S183000
Reexamination Certificate
active
11115394
ABSTRACT:
The present invention provides an improved method for treating lung cancer, preferably non-small cell lung cancer, by orally administering UFT to postoperative lung cancer patients.
REFERENCES:
patent: 6303583 (2001-10-01), Kusunoki
Fujii, S., et al., “Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tertahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents”Gann70:209-14, 1979.
Ikenaka, K., et al., Effect of uracil on metabolism of 5-fluorouracil in vitro, @Gann70:353-9, 1979.
Ho, D.H., et al., “Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-flourouracil infusion and oral uracil plus N1-(2′Tertahydrofuryl)-5-flourouracil”,Clin. Cancer Res. 4:2085-8, 1998.
Shimizu, E., et al., “A phase II study of UFT in non-small cell lug cancer”,Jpn. J. Cancer Chemother. 13:2970-3, 1986.
Keicho, N., et al., “Phase II study of UFT in patients with advanced non-small cell lung cancer,”Jpn. J. Clin. Oncol. 16:143-6, 1986.
Ichinose, Y., et al., A phase II trial of oral UFT and cisplatin in inoperable non-small cell lung cancer,Cancer75:2677-80, 1995.
Ichinose, Y., et al., “UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma,”Cancer88:318-23, 2000.
Saito, J., et al., “A phase II trial of oral UFT plus cisplation (CDDP) in patients with non-small cell lung cancer (NSCLC),”Lung Cancer31:285-93, 2001.
Ichinose, Y., et al., “UFT plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell long cancer: a multiinstitutional phase II trial,”Prog. Proc. Am. Soc. Clin. Oncol. 21:321a (Abstract), 2002.
Ichinose, Y., et al., “A phase II trial UFT plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer,”Oncology13(3):98-101, 1999.
Schiller, J.H., et al., “Comparison of four chemotherapy regimens for advanced non-small cell lung cancer,”N. Engl. J. Med. 346:92-8, 2002.
Vokes, E.E., et al., “Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431,”J. Clin. Oncol. 20:4191-8, 2002.
Wada, H., et al., Adjuvant chemotherapy after complete resection in non-small-cell lung cancer,J. Clin. Oncol. 14:1048-54, 1996.
Okimoto, N., et al., “A randomized controlled postoperative adjuvant chemotherapy trial of CDDP+VDS+UFT and UFT alone in comparison with operation only for non-small cell lung carcinomas (Second Study);”Jpn. J. Lung Cancer36:863-71, 1996.
Mountain, C.F., A new international staging system for lung cancer,Chest. 89(4):225s-33s, 1986.
WHO Handbook for Reporting Results for Cancer Treatment, Geneva: World Health Organization Offset Publication No. 48, 14-21, 1979.
Shirakusa, T., et al., “Lung cancer in Japan: Analysis of lung cancer registry for resected cases in 1994,”Jpn. J. Lung Cancer42:555-66, 2002.
Breathnach, O.S., et al., “Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease,”J. Thorac. Cardiovasc. Surg. 121:42-7, 2001.
Myrdal, G., et al., “Survival in primary lung cancer potentially cured by operation: influence of tumor stage and clinical characteristics,”Ann. Thorac. Surg. 75:356-63, 2003.
Noguchi, M., et al., “Small adenocarcinoma of the lung: histologic characteristics and prognosis,”Cancer75:2844-52, 1995.
Kodama, K., et al., “Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning,”Lung Cancer33:17-25, 2001.
Tanaka, F., et al., “Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer,” Br. J. Cancer 84:263-9, 2001.
Feld, R., et al., “Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer,”J. Natl. Cancer Inst. 85:299-306, 1993.
Ohta, M., et al., “Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer,”J. Thorac. Cardiovasc. Surg. 106:703-8, 1993.
Ichinose, Y., et al., “A Randomized Phase III Trial of Postoperative Adjuvant Chemotherapy in Patients with Completely Resected Stage IIIa-N2 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group (JCOG9304) Trial,”Prog. Proc. Am. Soc. Clin. Oncol. 20:311a (Abstract), 2001.
Scagliotti, G.V., et al., “Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer,”J. Natl. Cancer Inst. 95:1453-1461, 2003.
Tanaka, F., et al., “Postoperative oral administration of UFT for completely resected pathologic stage I non-small cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG), the 4thStudy,”Prog. Proc. Eur. Cancer Conference37:S29 (Abstract), 2001.
Tada, H., et al., “Randomized Study of Adjuvant Chemotherapy for Completely Resected Non-Small Cell Lung Cancer,”Prog. Proc. Am. Soc. Clin. Oncol. 21:313a (Abstract), 2002.
Endo, C., et al., “A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-East Japan Study Group for Lung-Cancer Surgery,”Lung Cancer40:181-6, 2003.
Imaizumi, M., et al., “A randomized trial of postoperative adjuvat chemotherapy for p-stage I non-small cell lung cancer (4thcooperative study),”Prog. Proc. World Conference41:S54 (Abstract), 2003.
Yonekura, K., et al., “UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice,”Clin. Cancer Res. 5:2185-91, 1999.
Hamada, C., et al., “Efficacy or oral UFT for adjuvant chemotherapy after complete resection of non-small cell lung cancer: Meta-analysis of six randomized trials in 2003 patients,”Prog. Proc. Euro. Cancer Conference39:S231 (Abstract), 2003.
Mountain, C.F., “Revisions in the International System for Staging Lung Cancer,”Chest111(6):1710-17, 1997.
Mountain, C.F., et al., “Regional Lymph Node Classification for Lung Cancer Staging,”Chest111(6):1718-1723, 1997.
Schoenfeld, D.A., et al., “Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint,”Biometrics38:163-170, 1982.
Haybittle, J.L., “Repeated assessment of results in clinical trials of cancer treatment,”Br. J. Radiol. 44:793-797, 1971.
Kato, H., et al., “A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I (T1N0M0, T2N0M0) adenocarcinoma of the lung,”Proc. Am. Soc. Clin. Oncol. 22:621, 2003 (Abstract 2498).
Ichinose Yukito
Kato Harubumi
Ohta Mitsuo
Tsuboi Masahiro
Wada Hiromi
Graffeo Michel
Marschel Ardin H.
Rothwell Figg Ernst & Manbeck P.C.
Taiho Pharmaceutical Co. Ltd.
LandOfFree
Postoperative adjuvant chemotherapy with UFT does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Postoperative adjuvant chemotherapy with UFT, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Postoperative adjuvant chemotherapy with UFT will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3806886